Bradykinin receptor ligands: therapeutic perspectives

被引:0
|
作者
François Marceau
Domenico Regoli
机构
[1] Centre de Recherche,
[2] Centre Hospitalier Universitaire de Québec,undefined
[3] Pavillon L'Hôtel-Dieu de Québec,undefined
[4] 11 Côte-du-Palais,undefined
[5] Institute of Pharmacology,undefined
[6] Faculty of Medicine,undefined
[7] University of Ferrara,undefined
[8] Via F. di Mortara 19,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The kallikrein–kinin system consists of the precursor kininogens, the proteolytic kallikrein enzymes, the kinin peptides (which are produced through cleavage of kininogens by kallikreins) and two G-protein-coupled receptors (GPCRs), termed the B1 and B2 receptors, that mediate the biological effects of kinin peptides.The growing knowledge of the biological role of kinins has fuelled the development of potent and selective kinin receptor modulators as potential therapeutics.This medicinal chemistry effort, which was initiated with peptides in the 1970s, has now culminated in the production of a number of novel non-peptide antagonists, some of which are awaiting clinical trials.This article provides an overview of the kinin biology that is relevant to the roles of kinins in disease, and then considers the potential of kinin receptor modulators in various disease indications, including inflammation and pain.
引用
收藏
页码:845 / 852
页数:7
相关论文
共 50 条
  • [31] Bradykinin B1 Receptor Antagonists as Potential Therapeutic Agents for Pain
    Huang, Hui
    Player, Mark R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5383 - 5399
  • [32] Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives
    Baiula, Monica
    Spampinato, Santi
    Gentilucci, Luca
    Tolomelli, Alessandra
    FRONTIERS IN CHEMISTRY, 2019, 7
  • [33] New perspectives for the development of selective metabotropic glutamate receptor ligands
    Pin, JP
    De Colle, C
    Bessis, AS
    Acher, F
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 375 (1-3) : 277 - 294
  • [34] Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives
    Comai, Stefano
    Lopez-Canul, Martha
    De Gregorio, Danilo
    Posner, Ada
    Ettaoussi, Mohamed
    Guarnieri, Fabrizia Claudia
    Gobbi, Gabriella
    PHARMACOLOGICAL RESEARCH, 2019, 144 : 343 - 356
  • [35] Bradykinin receptors as a therapeutic target
    Howl, J
    Payne, SJ
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (02) : 277 - 285
  • [36] Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals
    Hashimoto, Kenji
    Ishiwata, Kiichi
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (30) : 3857 - 3876
  • [37] Pharmacology and therapeutic applications of A1 adenosine receptor ligands
    Dhalla, AK
    Shryock, JC
    Shreeniwas, R
    Belardinelli, L
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (04) : 369 - 385
  • [38] The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes
    Boehm, BO
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (09) : 1501 - 1509
  • [39] In silico drug discovery of melatonin receptor ligands with therapeutic potential
    Elisi, Gian Marco
    Scalvini, Laura
    Lodola, Alessio
    Bedini, Annalida
    Spadoni, Gilberto
    Rivara, Silvia
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (04) : 343 - 354
  • [40] Prophylactic and therapeutic implications of toll-like receptor ligands
    Hedayat, Mona
    Takeda, Kiyoshi
    Rezaei, Nima
    MEDICINAL RESEARCH REVIEWS, 2012, 32 (02) : 294 - 325